Regulatory Concerns Hit Neurocrine Biosciences: A Closer Look at NBIX's Safety Woes
Neurocrine Biosciences faces scrutiny after seven patient deaths linked to its drug raise regulatory alarm bells.
Replimune's FDA Approval: A New Chapter for Melanoma Treatment and Investment
Replimune secures FDA accelerated approval for TUDRIQEV, a significant milestone for melanoma treatm…
H&R REIT's C$6.7 Billion Take-Private: A Game Changer for Canadian Real Estate?
H&R REIT's C$6.7 billion acquisition could reshape the Canadian commercial real estate landscape.
Thoma Bravo's C$650M Acquisition of Kneat: What It Means for the Canadian Tech Landscape
Thoma Bravo's C$650M acquisition of Kneat signals a pivotal shift in the Canadian tech market amidst…
PDS Biotech Shifts Focus to PDS0301: Implications for Investors
PDS Biotech's strategic pivot towards PDS0301 raises intriguing questions for investors.
Amneal Pharmaceuticals Strengthens Market Position with Kashiv BioSciences Acquisition
Amneal's acquisition of Kashiv BioSciences positions it as a leader in the biosimilars market, enhan…
Jazz Pharmaceuticals Expands Pipeline with $1.32 Billion Acquisition of Actio Biosciences
Jazz Pharmaceuticals announces $1.32 billion acquisition of Actio Biosciences, enhancing its rare di…
AbCellera Biologics Stock Soars on Positive Phase 2 Trial Results
AbCellera's shares surged 30.3% after positive Phase 2 trial results for its innovative antibody, AB…
Teledyne's $1.1B Deal for Varex Imaging: Analyzing Market Implications
Teledyne's acquisition of Varex Imaging boosts shares and reshapes the medical imaging landscape.
Amneal Pharmaceuticals' Strategic Move: Acquisition of Kashiv BioSciences
Amneal's acquisition of Kashiv BioSciences positions it as a leader in the biosimilars market, indic…